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Essentials
• Sinus thrombosis may play a crucial role in development of dural arteriovenous fistula (DAVF).
• Little is known about the association between gene polymorphism and the development of DAVF.
• MMP-2-1306 C/T showed a higher prevalence rate in DAVF cases with sinus thrombosis.
• MMP-2-1306C/T polymorphism is likely a potential risk factor for sinus thrombosis in DAVF.
Summary. Background: Dural arteriovenous fistula (DAVF) is a rare but important cerebrovascular disorder in adults. Little is known about the molecular genetic pathogenesis underlying DAVF development. Objectives: To investigate the associations of gene polymorphisms and DAVF. Materials and Methods: By the use of real-time PCR genotyping, seven single-nucleotide polymorphisms (SNPs) of angiogenesis-related genes were analyzed in 72 DAVF patients. Pertinent clinical and imaging data were subgrouped on the basis of location (cavernous sinus versus lateral sinus), lesions (single versus multiple), cerebral venous reflux (CVR) grading (Borden I versus Borden II/III), and sinus thrombosis (with versus without). Results: We found that individuals carrying the polymorphic allele of matrix metalloproteinase Introduction DAVF is an abnormal direct connection between dural arteries and the venous sinuses or cortical veins. DAVF accounts for approximately 10-15% of all intracranial vascular malformations [1] . Multiple DAVFs at separate locations in the same patient have also been reported, accounting for ⁓ 8% of all such cases [2] . Its pathogenesis remains controversial. Initially thought to be of congenital origin, it is now generally considered to be an acquired type of intracranial vascular malformation [3] .
A few studies have investigated the association between single-nucleotide polymorphisms (SNPs) and sporadic brain arteriovenous malformations, with the aim of assessing the potential ability of specific SNPs to influence their molecular genetic pathogenesis [4, 5] , but, currently, little is known about the association between SNPs and DAVF development. SNPs are point variations in the DNA sequence that occur when a single nucleotide (A, T, G, or C) appears in a specific genome position. SNPs are of considerable clinical importance, as they are the most common forms of genetic variation, and they are related to the susceptibility to and clinical course of specific diseases [6] . The identification of SNPs associated with DAVFs might help us to understand the biological mechanisms underlying the pathogenesis and natural history of this disease, which may lead to the development of personalized therapies. The present study was conducted to investigate the relationship between gene polymorphisms and DAVFs.
Methods

Study population
The study population comprised 72 DAVF patients who presented to the authors' hospitals. In all cases, the diagnosis of DAVF was based on the results of brain magnetic resonance angiography and digital subtraction angiography. Pertinent clinical characteristics, including age, gender, location (cavernous sinus versus lateral sinus), lesions (single versus multiple), cerebral venous reflux (CVR) grading (Borden I versus Borden II/III), and sinus thrombosis (with versus without), were recorded. Written informed consent was obtained from each patient after the nature and purpose of the study had been fully explained, and the study was approved by the Institutional Review Board of the hospital's ethics committee.
Genotyping
Genomic DNA from the DAVF group was isolated from peripheral blood with the QIAamp DNA blood mini kit (Qiagen, Hilden, Germany), and used as the template for PCR. A total of seven SNPs, i.e. matrix metalloproteinase (MMP)-2-1306 (rs243865), MMP-9 (rs17576), MMP-9 (rs9509), tissue inhibitor of metalloproteinase (TIMP)-1 (rs4898), TIMP-2 (rs2277698), vascular endothelial growth factor A (VEGFA) (rs2010963), and VEGFA (rs3025039), were selected for this study, as these SNPs have been suggested to be associated with angiogenesis [7, 8] . Allelic discrimination of the seven SNPs was performed with the ABI StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) by use of the TaqMan assay. The volume of the reaction mix was 5 lL, consisting of 10 ng of genomic DNA, 2.5 lL of TaqMan Genotyping Master Mix, and 0.125 lL of TaqMan probe mix. The real-time PCR reaction was performed with an initial denaturation step at 95°C for 10 min, followed by 40 cycles thereafter, each consisting of 95°C for 15 s and 60°C for 1 min. After the fluorescence level had been measured, the allele frequencies were detected by the use of SDS v3.0 (Applied Biosystems) with the TaqMan assay. MMP-2-1306 (rs243865), MMP-9 (rs17576), MMP-9 (rs9509), TIMP-1 (rs4898), TIMP-2 (rs2277698), VEGFA (rs2010963), and VEGFA (rs3025039), in DAVF patients. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated whenever the v 2 test or Fisher's exact test showed significance. A P-value of < 0.05 was considered to be statistically significant.
Results
Clinical and angiographic data
The characteristics of the 72 DAVF patients are summarized in Table 1 . The mean age was 61.3 AE 12.7 years. The cohort of DAVF patients included: 38 men (52.8%) and 34 women (47.2%); 52 patients with single lesions (72.2%) and 20 patients with multiple lesions (27.8%); 27 patients with cavernous sinus involvement (37.5%) and 45 patients with non-cavernous sinus (62.5%); 35 patients with Borden I (48.6%) and 37 patients with Borden II/III (51.4%); and 56 patients without sinus thrombosis (77.8%) and 16 patients with sinus thrombosis (22.2%).
Association of SNPs in DAVF patients
The distribution of the SNPs and allele frequencies of MMP-2-1306 (rs243865), MMP-9 (rs17576), MMP-9 (rs9509), TIMP-1 (rs4898), TIMP-2 (rs2277698), VEGFA (rs2010963) and VEGFA (rs3025039) are shown in Table 2 . Associations of SNPs in DAVF patients subgrouped according to sinus thrombosis, CVR grading, location and lesion numbers are shown in Tables 3-6 . The MMP-2-1306 C/T and MMP-2-1306 C/T+T/T carriers had a significantly increased risk of sinus thrombosis as compared with the CC homozygotes (respectively: P = 0.006, OR 6.2 [95% CI 1.7-22.9]; P = 0.010, OR 4.7 [95% CI 1.4-16.1]). There was no difference in the other six gene polymorphisms between patients with sinus thrombosis and patients without sinus thrombosis (P > 0.05) ( Table 3 ). There was a weak difference in associations of TIMP-2 (rs2277698) gene polymorphism and DAVF patients subgrouped by CVR grading (P = 0.026; OR 3.0 [95% CI 1.1-8.2]). There was no difference in the other six gene polymorphisms between patients subgrouped by CVR (P > 0.05) ( Table 4 ). There were no differences in any of the polymorphisms of the seven genes between patients with cavernous sinus involvement and those with lateral sinus involvement, or between patients with single lesions and those with multiple lesions (P > 0.05) ( Tables 5 and 6 ).
Discussion
The present study investigated the associations of MMP-2-1306 (rs243865), MMP-9 (rs17576), MMP-9 (rs9509), TIMP-1 (rs4898), TIMP-2 (rs2277698), VEGFA (rs2010963) and VEGFA (rs3025039) polymorphisms with DAVF. A strong association between the MMP-2-1306 C/T polymorphism and sinus thrombosis in DAVF patients was found. The pathogenesis of DAVF formation is not fully understood. More recent data suggest that cerebral sinus thrombosis and venous hypertension may play an important role in DAVF development. It has been proposed that impaired venous outflow favors the development of Table 2 Distribution frequency of genetic polymorphisms of angiogenesis-related genes in 72 patients with dural arteriovenous fistulas
MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; VEGFA, vascular endothelial growth factor A. indigenous dysplastic dural vessels within the sinus, establishing a direct artery-to-sinus communication and causing the pre-existing intrinsic arteriovenous channel to open [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Venous hypertension may result in chronic focal cerebral hypoperfusion, thus upregulating hypoxia-inducible factor-1a, which subsequently increases vascular endothelial growth factor (VEGF) expression, thereby inducing aberrant angiogenesis and DAVF formation [9] [10] [11] [12] . This hypothesis is supported by previous findings showing that cerebral venous hypertension established by anastomosis of the common carotid artery and external jugular vein in rats and rabbits was associated with high angiogenic activity, increased VEGF expression, and DAVF formation [9, 11, 12, 19] . In addition, Li et al. reported that the rate of DAVF induction by venous hypertension in rats was reduced by the VEGF receptor antagonist, owing to reduced angiogenesis in the dura mater [15] . Many DAVF patients present with concomitant sinus thrombosis, mainly located in the sinus proximal to the DAVF [3, 20] . Turbulent blood flow induced by arteriovenous shunt injures the venous endothelium, thus predisposing the vein to occlusion [21] . Sinus thrombosis may serve as the primary event, and dural venous hypertension subsequently induces DAVF development [9, 10, 17] . Sinus thrombosis may not only play an important role in DAVF development, but may also result from the DAVF, possibly further inducing retrograde flow and exacerbating the severity of the clinical presentation. In our study, 13 of 16 (81.2%) patients with sinus thrombosis had high-grade CVR and Borden II or III, but only 24 of 56 (42.9%) patients without sinus thrombosis had high-grade CVR. A few studies have investigated the molecular genetic pathogenesis of brain arteriovenous malformation, but there are very limited data in the literature on the molecular genetic pathogenesis underlying DAVF development. Kraus et al. studied the associations between thrombophilic risk factors and DAVFs, and concluded that factor V Leiden is of pathogenetic significance in the etiology of a subgroup of DAVFs, but major roles of prothrombin G20210A, methylenetetrahydrofolate reductase C677T, b-fibrinogenG455A, plasminogen activator inhibitor-1 4G/5G and FXIII Val34Leu in the pathogenesis of DAVF were ruled out [22, 23] . In our study, only one SNP, MMP-2-1306 C/T, was associated with a significantly increased risk of sinus thrombosis as compared with the CC homozygotes (P = 0.006, OR 6.2 [95% CI 1.7-22.9] ). In a similar study, Ortak et al. reported that retinal vein occlusion might be associated with gene polymorphisms affecting the expression of MMP-2 [24] . MMPs constitute a large group of zincdependent proteases responsible for the degrading and remodeling of extracellular matrix components, such as elastin and type IV collagen [25] . Expression of MMP-2 is mostly regulated through cis-acting regulatory elements in the promoter, and is therefore subject to regulation by transcription factors and affected by SNPs in the promoter region. The MMP-2 rs2285053 C allele has higher promoter activity and mRNA expression than the T allele [26] . Therefore, it is postulated that the C allele has a stronger ability to digest extracellular matrix proteins, and might be a protective factor against sinus thrombosis. In addition, MMPs are involved in platelet functioning [27] . MMP-2 is stored in latent form in the platelet cytoplasm, and platelet aggregation may be mediated via the release of MMP-2 from platelets [28] . Thrombin-stimulated platelet adhesion to fibrinogen has been associated with increased release of MMP-2 from platelets [29] . MMP-2 exerts a proaggregatory effect [30] . To date, MMP-2-1306 C/T gene polymorphisms have not been reported as potential risk factors for sinus thrombosis in DAVF patients.
TIMP-2, the main endogenous inhibitor of MMP-2, is responsible for regulating the functions of MMPs [31] . The MMP-2/TIMP-2 expression ratio is an important factor in certain nervous and vascular disorders [24, [32] [33] [34] [35] . In our study, the TIMP-2 (rs2277698) gene polymorphism was shown to be weakly associated with DAVF patients subgrouped by CVR grading (P = 0.026; OR 3.0 [95% CI 1.1-8.2]). The imbalance between MMP-2 and TIMP-2 may be related to sinus thrombosis and further progression to high-grade cerebral venous reflux in DAVF patients. Further large-scale investigation is needed for clarification.
Personalized medicine is a rapidly progressing field with immense future potential in both diagnostics and therapeutics, especially given the recent advances in CRISPR/ Cas9 genome-editing technology [36] . Identifying molecular and genetic biomarkers will have an impact on the field of cerebrovascular medicine. According to the results of this study, the MMP-2-1306 C/T polymorphism was specifically associated with DAVFs and sinus thrombosis. We hypothesize that DAVF patients who are MMP-2-1306 C/T carriers may have a greater risk of developing sinus thrombosis and may even progress from low-grade to high-grade CVR. MMP-2-1306 C/T may be a useful predictor of the characteristics and progression of DAVFs.
This study has several limitations. Gene variants have been shown to vary among populations with different ethnic origins. The MMP-2-1306 T allele frequency varies among ethnicities, with different rates having been reported in Taiwan (15%), China (12%), Sweden (26%), the USA (24%), India (19%) [26] , and Turkey (9%) [24, 37, 38] . Second, a limited number of SNPs of angiogenesis-related genes were selected in this study. Furthermore, the numbers of DAVF cases were low, because it is a rare condition. Thus, further studies are required with more candidate SNPs and a larger sample size to verify the results of this study.
Conclusion
The gene variant MMP-2-1306 C/T showed a significantly higher prevalence in DAVF patients with sinus thrombosis. Our data suggest that the MMP-2-1306 C/T polymorphism is probably a risk factor for sinus thrombosis in DAVF patients. 
